Skip to main content

Table 1 Characteristics of participants

From: Long-term platinum retention after treatment with cisplatin and oxaliplatin

 

Cisplatin

Oxaliplatin

Gender (m/f)

13 m/7 f

20 m/5 f

Age at time of follow-up (median)

49 years

64 years

Duration of follow-up

18–75 months (median 41)

8–33 months (median 18)

Tumour type

Testicular carcinoma (9)

Colorectal carcinoma (25)

 

Yolk sac carcinoma (1)

 
 

Non small cell lung cancer (1)

 
 

Small cell lung cancer (1)

 
 

Head and neck carcinoma (8)

 

Cumulative dose

300–600 mg/m2 cisplatin (median 350)

585–1170 mg/m2 oxaliplatin (median 878)

 

195–390 mg/m2 Pt

287–575 mg/m2 Pt

 

(median 227)

(median 431)

Sodium thiosulfate

5 head and neck carcinoma patients treated intra-arterially with 600 mg/m2 cisplatin

NA

Ca/Mg infusion

NA

24/25

GSTM1

8/20 positive, 12/20 negative

10/25 positive, 15/25 negative

GSTT1

17/20 wildtype, 3/20 negative

21/25 positive, 4/25 negative

GSTP1

12/20105Ile/105Ile-GSTP1

9/25105Ile/105Ile-GSTP1

 

7/20105Val/105Ile-GSTP1

10/25105Val/105Ile-GSTP1

 

1/20105Val/105Val-GSTP1

6/25105Val/105Val-GSTP1

  1. NA = not applicable